Properties (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
gptkb:goserelin
|
| gptkbp:brand |
gptkb:Zoladex
|
| gptkbp:chemicalFormula |
C64H86N18O13S
|
| gptkbp:clinicalTrials |
Phase II
Phase III Phase I |
| gptkbp:contraindication |
pregnancy
hypersensitivity_to_goserelin |
| gptkbp:dosageForm |
depot injection
|
| gptkbp:drugInterdiction |
excreted in urine
subcutaneous absorption metabolized in liver gonadotropin-releasing hormone agonist |
| gptkbp:duration |
28 days
|
| gptkbp:endOfLife |
2 to 4 hours
|
| gptkbp:firstAppearance |
1989
|
| gptkbp:formFactor |
implant
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zoladex
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mandates |
endometriosis
advanced breast cancer central precocious puberty uterine fibroids advanced prostate cancer |
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:United_Kingdom gptkb:United_States |
| gptkbp:operates_in |
L02AE01
|
| gptkbp:patentExpiration |
2010
2015 2020 2025 |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:sideEffect |
fatigue
headache nausea weight gain injection site reactions mood changes hot flashes decreased libido |
| gptkbp:usedFor |
breast cancer
prostate cancer endometriosis precocious puberty |
| gptkbp:weight |
1439.67 g/mol
|